MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
Metrics: PDF 1180 views | HTML 1317 views | ?
Toril Holien1, Kristine Misund1, Oddrun Elise Olsen1, Katarzyna Anna Baranowska1, Glenn Buene1, Magne Børset1,2, Anders Waage1,3, Anders Sundan1,4
1K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
2Department of Immunology and Transfusion Medicine, St. Olav’s University Hospital, Trondheim, Norway
3Department of Hematology, St. Olav’s University Hospital, Trondheim, Norway
4CEMIR (Centre of Molecular Inflammation Research), Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
Toril Holien, e-mail: firstname.lastname@example.org
Keywords: oncology, carcinogenesis, molecular and cellular biology, signal transduction, cell cycle
Received: March 09, 2015 Accepted: May 20, 2015 Published: June 02, 2015
In multiple myeloma, elevated MYC expression is related to disease initiation and progression. We found that in myeloma cell lines, MYC gene amplifications were common and correlated with MYC mRNA and protein. In primary cell samples MYC mRNA levels were also relatively high; however gene copy number alterations were uncommon. Elevated levels of MYC in primary myeloma cells have been reported to arise from complex genetic aberrations and are more common than previously thought. Thus, elevated MYC expression is achieved differently in myeloma cell lines and primary cells. Sensitivity of myeloma cell lines to the MYC inhibitor 10058-F4 correlated with MYC expression, supporting that the activity of 10058-F4 was through specific inhibition of MYC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.